Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Analysis: Healthy babies born after accelerated elimination of teriflunomide
4-aminopyridine toxicity: a case report and review of the literature.
Testing effects of glatiramer acetate and fingolimod in an infectious model of CNS immune surveillance.
Self-reactive CD4(+) T cells activated during viral-induced demyelination do not prevent clinical recovery.
Immunological Markers for PML Prediction in MS Patients Treated with Natalizumab.
Dynamic regulatory network controlling TH17 cell differentiation.
Quality of life and depression in multiple sclerosis patients: longitudinal results of the BetaPlus study.
Stimulated PBMC-produced IFN-γ and TNF-α are associated with altered relapse risk in multiple sclerosis: results from a prospective cohort study.
Application of fullerenes in nanomedicine: an update.
Mountain View Pharmaceuticals receives European patent on potential long-acting drug for multiple sclerosis
Human herpesvirus 6 and effectiveness of interferon β1b in multiple sclerosis patients.
Effect of Treatment Regimen on the Immunogenicity of Human Interferon Beta in Immune Tolerant Mice.
BTG Commences Phase IIa Study of Multiple Sclerosis
Multiple sclerosis.
Effects of an aqueous extract of North American ginseng on MOG((35-55))-induced EAE in mice.
Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota.
A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis.
Exercise and disease progression in multiple sclerosis: can exercise slow down the progression of multiple sclerosis?
Immunomodulatory drugs (natalizumab), worsening of multiple sclerosis, rebound effect and similitude.
Long-Term Safety and Efficacy Study of BIIB017 (PEGylated Interferon Beta-1a) (ATTAIN)
Neuroprotective effects of recombinant T-cell receptor ligand in autoimmune optic neuritis in HLA-DR2 mice.
First patient treated in Mapi Pharma's Phase IIa clinical trial of GA Depot for relapsing remitting multiple sclerosis (RRMS)
Idebenone for primary progressive multiple sclerosis
[The Sjögren's syndrome and multiple sclerosis: similarity and differences.]
Roche's new time-saving subcutaneous formulation of MabThera approved in Europe for the treatment of common forms of non-Hodgkin Lymphoma

Pages